BIODESIX INC
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
On August 12, 2026, Perceptive exercised all 375,000 outstanding warrants associated with the Perceptive Warrant, First Amendment Warrants, and the Sixth Amendment Warrants on a cashless basis and received 228,691 shares of the Company's common stock.
No underwriters were involved in the foregoing sale of securities. The common stock issued upon exercise of the Perceptive Warrant, First Amendment Warrants, and the Sixth Amendment Warrants was issued in reliance upon the exemption from registration provided by Section 3(a)(9) under the Securities Act. The resale by Perceptive of the common stock issued upon exercise of these warrants was registered with the Securities and Exchange Commission on Form S-3 (Registration No. 333-296122), filed on May 21, 2026. We will not receive any proceeds from resales by Perceptive.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.